Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy (Q39146408)

9 September 2017

Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy (English)

1 reference

9 September 2017

1 reference

1 reference

4

Roland E Kontermann

1 reference

9 September 2017

Nora Hornig

1

1 reference

9 September 2017

Katharina Reinhardt

series ordinal

2

1 reference

9 September 2017

Vanessa Kermer

series ordinal

3

1 reference

9 September 2017

Dafne Müller

series ordinal

5

1 reference

9 September 2017

30 May 2013

1 reference

Cancer Immunology, Immunotherapy

9 September 2017

1 reference

9 September 2017

62

1 reference

9 September 2017

8

1 reference

9 September 2017

1369-1380

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-013-1441-7

9 September 2017

0 references

cites work

Immunotherapy earns its spot in the ranks of cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Modulation of GITR for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Eradication of established tumors in mice by a combination antibody-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Costimulatory and coinhibitory receptors in anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Tumor-specific crosslinking of GITR as costimulation for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

The molecular architecture of the TNF superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Targeted cancer immunotherapy using ligands of the tumor necrosis factor super-family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Tumor therapeutics by design: targeting and activation of death receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Sequence, structure, function, immunity: structural genomics of costimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

4-1BBL costimulation retrieves CD28 expression in activated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1441-7

10.1007/S00262-013-1441-7

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference